# Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma

> **NCT02319889** · EARLY_PHASE1 · TERMINATED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 3 (actual)

## Conditions studied

- Stage I Non-Small Cell Lung Cancer
- Stage II Non-Small Cell Lung Cancer

## Interventions

- **RADIATION:** Stereotactic Body Radiotherapy
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel Albumin-Stabilized Nanoparticle Formulation

## Key facts

- **NCT ID:** NCT02319889
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-02-02
- **Primary completion:** 2016-07-06
- **Final completion:** 2017-01-19
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Funding unavailable
- **Last updated:** 2017-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02319889

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02319889, "Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02319889. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*